ESMO Open最新文献

{"title":"15P Germline predictors of recurrence in patients with ER-positive and HER2-negative breast cancer: A GWAS analysis of multiple cohorts totaling 10,640 patients","authors":"","doi":"10.1016/j.esmoop.2024.103761","DOIUrl":"10.1016/j.esmoop.2024.103761","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"84P Quinacrine inhibits angiogenesis and migration of non-small cells lung cancer cells (NSCLC) by binding with the kinase domain of VEGFR2","authors":"","doi":"10.1016/j.esmoop.2024.103825","DOIUrl":"10.1016/j.esmoop.2024.103825","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"26P Predictive biomarker discovery for ICI treatment response in metastatic MMRd endometrial cancer through deep proteomic profiling of FFPE tissue samples","authors":"","doi":"10.1016/j.esmoop.2024.103772","DOIUrl":"10.1016/j.esmoop.2024.103772","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"80P Suppression of glioblastoma progression by FDA-approved central nervous system-accumulating drugs via autophagy modulation and ER stress-induced apoptosis","authors":"","doi":"10.1016/j.esmoop.2024.103821","DOIUrl":"10.1016/j.esmoop.2024.103821","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142531289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"19P Single-cell transcriptomic and cell-cell communication profiles in breast cancer responders to chemotherapy or chemo-immunotherapy","authors":"","doi":"10.1016/j.esmoop.2024.103765","DOIUrl":"10.1016/j.esmoop.2024.103765","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142525906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"54P Integrative omics workflow identifies credible druggable targets in high-grade serous cancer","authors":"","doi":"10.1016/j.esmoop.2024.103799","DOIUrl":"10.1016/j.esmoop.2024.103799","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"12P Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial","authors":"","doi":"10.1016/j.esmoop.2024.103758","DOIUrl":"10.1016/j.esmoop.2024.103758","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations","authors":"","doi":"10.1016/j.esmoop.2024.103731","DOIUrl":"10.1016/j.esmoop.2024.103731","url":null,"abstract":"<div><h3>Background</h3><div>Somatic genetic alterations of the estrogen receptor 1 gene (<em>ESR1</em><em>)</em> are enriched in endocrine therapy-resistant, estrogen receptor-positive (ER+) metastatic breast cancer (mBC). Herein, we investigated and compared the clinical and genomic landscape of <em>ESR1</em>-mutant (<em>ESR1</em>^<em>MUT</em>) and <em>ESR1</em> wild type (<em>ESR1</em>^<em>WT</em>) ER+/ human epidermal growth factor receptor 2 (HER2)− mBCs.</div></div><div><h3>Methods</h3><div>Clinical and genomic data were retrieved from cBioPortal using the publicly-available MSK MetTropism dataset. Metastatic, ER+/HER2− mBC samples were included in the analysis. Only oncogenic and likely oncogenic alterations according to OncoKB were included. Statistical analyses were carried out using alpha level of 0.05, with a false discovery rate threshold of 10% for multiple comparisons using the Benjamini–Hochberg method.</div></div><div><h3>Results</h3><div>Among 679 samples, 136 <em>ESR1</em>^<em>MUT</em> among 131 tumors were found (19.2%). The frequency of <em>ESR1</em>^<em>MUT</em> was higher in ductal versus lobular mBC (21.2% versus 13.8%, <em>P =</em> 0.052) and enriched in liver metastasis compared with other sites (22.5% versus 12.7%; <em>q =</em> 0.02). Compared with <em>ESR1</em>^<em>WT</em> mBC, <em>ESR1</em>^MUT tumors showed higher fraction of genome altered (FGA) {[0.28 interquartile range (IQR), 0.15-0.43] versus 0.22 (0.11-0.38); <em>P</em> = 0.04} and tumor mutational burden (TMB) [4.89 (IQR 3.46-6.85) versus 3.92 (2.59-6.05) mut/Mb; <em>P</em> = 0.001]. Tumors harboring p.E380X alterations showed higher TMB compared with those with H11-12 alterations [8.24 (IQR 5.06-15.3) versus 4.89 (IQR 3.46-6.75) mut/Mb<em>; P</em> = 0.01]. Genetic alterations of <em>TP53</em> were enriched in <em>ESR1</em>^<em>WT</em> tumors (36% versus 14%) [odds ratio (OR) 3.17, 95% confidence interval (CI) 1.88-5.64, <em>q</em> = 0.001]. Considering signaling pathways, <em>ESR1</em>^<em>MUT</em> tumors showed a lower occurrence of <em>TP53</em> (OR 0.48, 95% CI 0.30-0.74; <em>q</em> = 0.003) and <em>MAPK</em> (OR 0.29, 95% CI 0.11-0.65; <em>q</em> = 0.009) alterations. <em>TP53</em> (<em>q</em> &lt; 0.001), <em>CDH1</em> (<em>q</em> &lt; 0.001), and <em>ERBB2</em> (<em>q</em> &lt; 0.001) demonstrated mutual exclusivity with <em>ESR1</em>^<em>MUT</em>.</div></div><div><h3>Conclusions</h3><div>ER+/HER2− mBCs carrying <em>ESR1</em>^<em>MUT</em> exhibit a divergent genomic background, characterized by a lower prevalence of <em>TP53</em> and <em>MAPK</em> pathway alterations. Less common <em>ESR1</em> alterations falling outside the H11-H12 region seem to occur in tumors with higher TMB, deserving further investigation to understand their potential actionability.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology","authors":"","doi":"10.1016/j.esmoop.2024.103932","DOIUrl":"10.1016/j.esmoop.2024.103932","url":null,"abstract":"<div><h3>Background</h3><div>Extravasation (EV), or the leakage of anticancer drugs into perivascular and subcutaneous tissues during intravenous administration, can cause serious conditions that may require surgical intervention. Therefore, updated guidelines for EV based on systematic review are needed. Additionally, classifications for anticancer drugs that cause EV are not standardized across the current guidelines, and some novel drugs have not been classified. Therefore, this study aimed to formulate guidelines using evidence-based information for shared decision making on prevention, early detection, treatment, and care for EV in Japan and provide additional classification for tissue injury based on systematic review.</div></div><div><h3>Materials and methods</h3><div>The members of the Japanese Society of Cancer Nursing (JSCN), Japanese Society of Medical Oncology (JSMO), and Japanese Society of Pharmaceutical Oncology (JASPO) were surveyed about significant clinical challenges related to EV, and 17 clinical questions (CQs) were formulated. PubMed and ICHUSHI Web were searched using the Patient, Intervention, Comparison, and Outcomes terms listed in each CQ as key words. For the classification of new drugs, articles published through February 2021 were selected using the search terms ‘extravasation’, ‘injection-site reaction’, ‘adverse events’, and the names of individual drugs as key words.</div></div><div><h3>Results</h3><div>Recommendations based on the results of randomized controlled trials (RCTs) were made with regard to the selection of central venous (CV) devices (CQ2, CQ3a, CQ3b, and CQ3c), regular replacement of peripheral venous catheters (CQ5), and use of fosaprepitant (CQ7). These CQs are novel and were not mentioned in previous guidelines. Warm compression monotherapy (CQ10b) and local injection of steroids (CQ12) are discouraged for the management of EV. Ten new drugs were classified for EV tissue injury.</div></div><div><h3>Conclusions</h3><div>This study provides updated guidelines for the prevention and treatment of EV, which can be used to help health care providers and patients and their families practice better EV management.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"74P The influence of genetic phenotype on prognosis of osteosarcoma","authors":"","doi":"10.1016/j.esmoop.2024.103922","DOIUrl":"10.1016/j.esmoop.2024.103922","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":null,"pages":null},"PeriodicalIF":7.1,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142526203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}